Firms: DLA Piper (Dechra Pharmaceuticals PLC); Bartier Perry (Apex Laboratories Pty Ltd)
Deal: Dechra Pharmaceuticals PLC has proposed an acquisition of Apex Laboratories Pty Ltd
Value: $55 million
Key players: The DLA Piper team was led by partner David Ryan (pictured) and senior associate James McCarthy, with assistance from intellectual property partner Melinda Upton, head of employment Nicholas Turner and solicitor Lauren Crossman.
Deal significance: International veterinary pharmaceuticals company Dechra Pharmaceuticals' proposed acquisition of privately owned Apex Laboratories Pty Ltd is valued at $55 million.
Established in 1962, Apex is Australia's leading manufacturer of generic and proprietary veterinary pharmaceuticals and pet care products for the Australian and New Zealand markets.
The acquisition is expected to be complete in mid-October, and includes the purchase of Apex's manufacturing site.
“We're delighted to have advised Dechra on the acquisition of Apex, with its complementary portfolio offering,” lead partner Mr Ryan said.
“The transaction will enable our client to expand their presence in the growing Australasian and Asian veterinary pharmaceutical and animal product markets.”